Life sciences venture capitalist Vesalius Biocapital III has announced the final close of the VBC III fund at €120m.
Erytech Pharma has inked a deal with SQZ Biotechnologies Inc. to develop new immune modulating therapies.

Sanofi‘s and Regeneron‘s IL-33 blocker REGN3500 met primary Phase II endpoint in asthma patients.

After the birth of the first genome-edited babies in China, regulators, researchers, and bioethics experts seek ways to ban clinical use of germline editing, in order to protect the innovative field from misuse for human enhancement and side effect-prone application forgene correction and human enhancement.

Karo Pharma AB announced it will acquire Trimb Holding AB for MSEK3,400 (€319.6m) and intends to carry out a Rights Issue of about MSEK 1,500 (€141m).

Deep Branch Biotechnology Ltd. from Nottingham has started a feasibility study with the British energy supplier Drax Group. The technology to be analysed converts carbon dioxide emitted by power stations into protein that could be used for feeding fish and livestock.

German GM proponents have taken action against discrimination of food products generated by gene editing.

Roche and US company Hesperos Inc have used human cancer and organ cells, placed in a 5-chamber microfluidic chip, to predict chemotherapy safety and efficacy preclinically.

Valo Therapeutics Limited, a cancer immunotherapy company developing neoantigen-coated oncolytic viruses as therapeutic vaccines has appointed Michael Stein to Chief Executive Officer. Stein already served as part-time co-Chairman since the company’s inception in 2017.

As food producers are taking up current health and sustainability trends more and more, the next EFIB (30 September?–?2 October, 2019) will see a lot of technology providers and ingredient producers showcasing biotechnological solutions in Brussels. European Biotechnology spoke with Dr Gerhard Schmid, Head, Wacker Biosolutions, about the market, challenges, and growth strategies within the bioeconomy.